IP Library › Granted Patent US 8,197,825
Granted Patent B2
US 8,197,825 · App. 12/814,602 · Granted Jun 12, 2012

Recombinant MVA virus and the use thereof

Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,197,825
App. No.
12/814,602
Granted
Jun 12, 2012
Kind
B2
Abstract

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

Claims (18)

1. A recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding a foreign antigen, wherein the DNA sequence is stably inserted into deletion site VI of the MVA.

2. The recombinant MVA of claim 1 , wherein the foreign antigen is a human immunodeficiency virus antigen.

3. The recombinant MVA of claim 2 , wherein the foreign antigen is an HIV nef antigen.

4. The recombinant MVA of claim 3 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

5. An isolated host cell comprising the recombinant MVA of claim 3 .

6. The recombinant MVA of claim 2 , wherein the foreign antigen is an HIV tat antigen.

7. The recombinant MVA of claim 6 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

8. An isolated host cell comprising the recombinant MVA of claim 6 .

9. The recombinant MVA of claim 2 , wherein the foreign antigen is an HIV gag antigen.

10. The recombinant MVA of claim 9 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

11. An isolated host cell comprising the recombinant MVA of claim 9 .

12. The recombinant MVA of claim 2 , wherein the foreign antigen is an HIV pol antigen.

13. The recombinant MVA of claim 12 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

14. An isolated host cell comprising the recombinant MVA of claim 12 .

15. The recombinant MVA of claim 2 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

16. An isolated host cell comprising the recombinant MVA of claim 2 .

17. The recombinant MVA of claim 1 , wherein expression of the foreign antigen is under the control of a vaccinia virus promoter.

18. An isolated host cell comprising the recombinant MVA of claim 1 .

Priority Claims (1)
DK 0782/95 · Jul 4, 1995 · national
Continuity (5)
Continuation 11522889 · Sep 19, 2006
Division 10147284 · May 15, 2002
Continuation 09002443 · Jan 2, 1998
Continuation PCTEP9602926 · Jul 3, 1996
Related Publication 20100291139A1 · Nov 18, 2010